Table 5.
Baseline characteristics of non-allergic individuals.
| Clinical and demographic characteristics | All patients n = 341 (%) | |||
|---|---|---|---|---|
| Gender | ||||
| Male | 119 (34.9) | |||
| Female | 222 (65.1) | |||
| Skin tests | ||||
| Grass positive | 66 (20.9) | |||
| Olive positive | 99 (31.3) | |||
| Profilin positive | 4 (1.3) | |||
| Polcalcin positive | 8 (2.7) | |||
| Allergy symptoms | ||||
| Rhinoconjunctivitis | ||||
| No | 64 (18.8) | |||
| Mild | 178 (52.2) | |||
| Moderate/severe | 99 (29.0) | |||
| Asthma | ||||
| No | 147 (43.1) | |||
| Mild | 137 (40.2) | |||
| Moderate-severe | 57 (16.7) | |||
| Immunotherapy | ||||
| No | 338 (100) | |||
| Grass and/or olive immunotherapy | 0 (0) | |||
| Mean | Median | SD* | IQR† | |
| Age | 30.1 | 29.0 | 15.0 | 18–41 |
| Total IgE (kU/L) | 239.8 | 82 | 526.2 | 33.8–232.5 |
| Lolium sIgE‡(kUA/L) | 1.3 | 0.1 | 6.9 | 0.0–0.5 |
| rPhl p 1,5 sIgE (kUA/L) | 3.0 | 0.4 | 12.4 | 0.0–1.2 |
| Olea sIgE (kUA/L) | 0.8 | 0.1 | 3.5 | 0.0–0.6 |
| Ole e 1 sIgE (kUA/L) | 1.2 | 0.3 | 4.6 | 0.0–0.8 |
| Ole e 7 sIgE (kUA/L) | 0.7 | 0.0 | 4.8 | 0.0–0.1 |
| Ole e 9 sIgE (kUA/L) | 0.1 | 0.0 | 0.3 | 0.0–0.0 |
SD*, standard deviation; IQR†, interquartile range; sIgE‡, specific Immunoglobulin E.